CN108342488A - 一种用于检测胃癌的试剂盒 - Google Patents
一种用于检测胃癌的试剂盒 Download PDFInfo
- Publication number
- CN108342488A CN108342488A CN201810457941.6A CN201810457941A CN108342488A CN 108342488 A CN108342488 A CN 108342488A CN 201810457941 A CN201810457941 A CN 201810457941A CN 108342488 A CN108342488 A CN 108342488A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- kit
- seq
- primer
- mutational site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 58
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 58
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 57
- 238000003745 diagnosis Methods 0.000 claims abstract description 22
- 206010064571 Gene mutation Diseases 0.000 claims abstract description 3
- 238000001514 detection method Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 239000012807 PCR reagent Substances 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 238000010025 steaming Methods 0.000 claims 1
- 230000000869 mutational effect Effects 0.000 abstract description 19
- 230000008859 change Effects 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 238000011156 evaluation Methods 0.000 abstract description 3
- 238000009007 Diagnostic Kit Methods 0.000 abstract description 2
- 230000001419 dependent effect Effects 0.000 abstract description 2
- 239000003596 drug target Substances 0.000 abstract description 2
- 229940126586 small molecule drug Drugs 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 17
- 230000035772 mutation Effects 0.000 description 15
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 14
- 238000012163 sequencing technique Methods 0.000 description 11
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 239000003471 mutagenic agent Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241000269335 Ambystoma laterale x Ambystoma jeffersonianum Species 0.000 description 2
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091028075 Circular RNA Proteins 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 description 1
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FRTNIYVUDIHXPG-UHFFFAOYSA-N acetic acid;ethane-1,2-diamine Chemical class CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCN FRTNIYVUDIHXPG-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005532 trapping Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
引物名称 | 引物序列 |
上游引物(SEQ ID NO:3) | atgtcttccagtaatgtcga |
下游引物(SEQ ID NO:4) | attacatttg acattggcag |
扩增结果 | |
10例胃癌患者 | 10例均为阳性,结果为360bp |
5例正常人 | 无扩增条带 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810457941.6A CN108342488B (zh) | 2018-05-14 | 2018-05-14 | 一种用于检测胃癌的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810457941.6A CN108342488B (zh) | 2018-05-14 | 2018-05-14 | 一种用于检测胃癌的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108342488A true CN108342488A (zh) | 2018-07-31 |
CN108342488B CN108342488B (zh) | 2021-02-19 |
Family
ID=62955525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810457941.6A Active CN108342488B (zh) | 2018-05-14 | 2018-05-14 | 一种用于检测胃癌的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108342488B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113215663A (zh) * | 2021-06-02 | 2021-08-06 | 中国科学院合肥物质科学研究院 | 一种基于高通量测序的胃癌靶向治疗基因组文库的构建方法及引物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104278085A (zh) * | 2014-09-15 | 2015-01-14 | 南京医科大学 | 一种与早发胃癌辅助诊断相关的snp标志物及其应用 |
WO2018050066A1 (zh) * | 2016-09-14 | 2018-03-22 | 北京大学 | 一种abcg2单克隆抗体及其用途 |
-
2018
- 2018-05-14 CN CN201810457941.6A patent/CN108342488B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104278085A (zh) * | 2014-09-15 | 2015-01-14 | 南京医科大学 | 一种与早发胃癌辅助诊断相关的snp标志物及其应用 |
WO2018050066A1 (zh) * | 2016-09-14 | 2018-03-22 | 北京大学 | 一种abcg2单克隆抗体及其用途 |
Non-Patent Citations (2)
Title |
---|
JUNQING WANG等: "ABCG2 confers promotion in gastric cancer through modulating downstream CRKL in vitro combining with biostatistics mining", 《ONCOTARGET》 * |
徐桂芳等: "VEGF-D、MMP-7在胃癌组织中的表达及其与预后的关系", 《胃肠病学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113215663A (zh) * | 2021-06-02 | 2021-08-06 | 中国科学院合肥物质科学研究院 | 一种基于高通量测序的胃癌靶向治疗基因组文库的构建方法及引物 |
CN113215663B (zh) * | 2021-06-02 | 2023-04-25 | 中国科学院合肥物质科学研究院 | 一种基于高通量测序的胃癌靶向治疗基因组文库的构建方法及引物 |
Also Published As
Publication number | Publication date |
---|---|
CN108342488B (zh) | 2021-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108753967A (zh) | 一种用于肝癌检测的基因集及其panel检测设计方法 | |
CN107475375A (zh) | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 | |
WO2015101175A1 (en) | Method and kit for non-invasively detecting egfr gene mutaions | |
CN107254531B (zh) | 早发性结直肠癌辅助诊断的遗传生物标志物及其应用 | |
CN106399304B (zh) | 一种与乳腺癌相关的snp标记 | |
CN110343748A (zh) | 基于高通量靶向测序分析肿瘤突变负荷的方法 | |
CN104988141B (zh) | BRCA2基因g.32912799T>C突变及其在乳腺癌辅助诊断中的应用 | |
CN102534009B (zh) | 一种与原发性肺癌辅助诊断相关的snp标志物及其应用 | |
CN104293919A (zh) | 一种与非吸烟女性肺癌辅助诊断相关的snp标志物及其应用 | |
CN107254546B (zh) | 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用 | |
CN111968702B (zh) | 一种基于循环肿瘤dna的恶性肿瘤早期筛查*** | |
CN107557468B (zh) | 一种与原发性肺癌辅助诊断相关的癌-睾丸基因遗传标志物及其应用 | |
CN108342488A (zh) | 一种用于检测胃癌的试剂盒 | |
CN109880903B (zh) | 一种用于非小细胞肺癌辅助诊断的snp标志物及其应用 | |
CN104946751B (zh) | BRCA1基因g.41244291delT突变及其在乳腺癌辅助诊断中的应用 | |
CN114350812A (zh) | 与奥西替尼耐药性相关的NSCLC-free RNA-3及其应用 | |
CN108441560B (zh) | 一种位于cep128基因的与放疗引起的放射性脑损伤相关的snp标志物及其应用 | |
CN110714079A (zh) | 一种用于乳腺癌辅助诊断的突变基因及其应用 | |
CA2559134A1 (en) | Target genes for inflammatory bowel disease | |
CN108424959B (zh) | 一种用于强直性脊柱炎早期诊断的生物标记物及其在试剂盒中应用 | |
CN106636351A (zh) | 一种与乳腺癌相关的snp标记及其应用 | |
CN106834476A (zh) | 一种乳腺癌检测试剂盒 | |
CN103923971A (zh) | 大肠直肠癌相关基因K-ras基因突变检测方法和相关检测试剂盒 | |
KR20190052397A (ko) | 다발성 골수종 환자에서 레날리도마이드 및 덱사메타손의 치료에 대한 예후 예측용 바이오 마커 | |
CN106834468B (zh) | Aim1和eme1易感snp位点检测试剂及其制备的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210129 Address after: Room 905, phase II industrial building, No.1109, gangxingsan Road, high tech Zone, Jinan City, Shandong Province Applicant after: YINFENG GENE TECHNOLOGY Co.,Ltd. Address before: Department of Gastroenterology, 307 Hospital, 8 dongdajie, Fengtai District, Beijing 100071 Applicant before: Gu Chao |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A reagent kit for detecting gastric cancer Granted publication date: 20210219 Pledgee: China Construction Bank Corporation Jinan Branch Pledgor: YINFENG GENE TECHNOLOGY Co.,Ltd. Registration number: Y2024980025943 |